Online citations, reference lists, and bibliographies.
← Back to Search

Absence Of Antibody Production In Patients Treated With Botulinum A Toxin.

A. W. Biglan, R. Gonnering, L. B. Lockhart, B. Rabin, F. H. Fuerste
Published 1986 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
To test the possibility of the formation of an antibody to botulinum A toxin after multiple injections of this potent neurotoxin, we collected serum samples from 28 patients who received 57 doses. These injections over a nine-month period with as much as 50 units per injection formed no detectable antibody.
This paper references
10.1111/J.1748-1716.1983.TB07317.X
Different effects of types A and B botulinum toxin on transmitter release at the rat neuromuscular junction.
L. Sellin (1983)
10.1016/0306-4522(84)90213-6
Comparative activities of tetanus and botulinum toxins
J. Mellanby (1984)
The neurotoxins of Clostridium botulinum and Clostridium tetani.
G. Wright (1955)
Pharmacologic weakening of extraocular muscles.
A. B. Scott (1973)
10.1001/ARCHOPHT.1981.03930011056015
Blepharospasm surgery. An anatomical approach.
W. Gillum (1981)
Comparison of the effects of botulinum neurotoxin types A and E at the rat neuromuscular junction.
Sellin Lc (1983)
10.1093/INFDIS/150.3.407
Antitoxin levels in botulism patients treated with trivalent equine botulism antitoxin to toxin types A, B, and E.
C. H. Hatheway (1984)
10.1093/MILMED/149.1.12
Botulism--an update.
L. Sellin (1984)
10.1016/S0161-6420(80)35127-0
Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery.
A. B. Scott (1980)
10.1016/S0006-291X(85)80009-7
Partial amino acid sequences of the heavy and light chains of botulinum neurotoxin type E.
V. Sathyamoorthy (1985)
Studies on botulinum toxoids, types A and B; immunization of man.
Reames Hr (1947)
10.1001/ARCHOPHT.1984.01040030216030
Treatment of essential blepharospasm. I. Comparison of facial nerve avulsion and eyebrow-eyelid muscle stripping procedure.
C. McCord (1984)
10.1001/ARCHOPHT.1984.01040031184014
Treatment of blepharospasm with botulinum toxin. A preliminary report.
B. Frueh (1984)
10.1001/ARCHOPHT.1985.01050030043017
Botulinum A toxin injection as a treatment for blepharospasm.
A. Scott (1985)
Botulinum toxin injection of eye muscles to correct strabismus.
A. B. Scott (1981)
10.1016/S0002-9394(14)77954-1
The use of botulinum toxin in blepharospasm.
N. Shorr (1985)
Treatment of facial spasm with oculinum (Clostridium botulinum toxin): a preliminary report.
A. W. Biglan (1986)
10.1016/0002-9394(85)90228-4
Treatment of blepharospasm with botulinum toxin.
E. A. Tsoy (1985)



This paper is referenced by
10.1080/14737175.2017.1262258
Immunological aspects of botulinum toxin therapy
D. Dressler (2017)
10.3109/08820539209065092
Botulinum toxin in ophthalmology
J. Holmes (1992)
10.1212/WNL.43.9.1715
Botulinum antibodies in dystonic patients treated with type A botulinum toxin
M. Zuber (1993)
10.1016/j.survophthal.2010.03.008
Review and update of involuntary facial movement disorders presenting in the ophthalmological setting.
A. Ross (2011)
10.1097/IIO.0000000000000201
The History of Blepharospasm in Medicine
Eric B Hamill (2018)
10.1212/WNL.46.1.26
Botulinum toxin therapy, immunologic resistance, and problems with available materials
G. Borodic (1996)
10.1111/j.1468-1331.1999.tb00033.x
Medium‐term response characterisation and risk factor analysis of botulinum toxin type A in the management of spasticity in children with cerebral palsy
R. Boyd (1999)
10.1016/S0966-6362(99)00054-5
Recommendations for the use of botulinum toxin type A in the management of cerebral palsy.
H. Graham (2000)
10.1016/J.EURURO.2004.11.009
Success of repeat detrusor injections of botulinum a toxin in patients with severe neurogenic detrusor overactivity and incontinence.
J. Grosse (2005)
10.1001/ARCHOTOL.1989.01860310120038
Management of Facial Spasm With Clostridium botulinum Toxin-Reply
A. W. Biglan (1989)
10.1002/MDS.870090216
Development of resistance to botulinum toxin type A in patients with torticollis
P. Greene (1994)
10.1111/j.1468-1331.2006.01439.x
Immunological aspects of Botox®, Dysport® and MyoblocTM/NeuroBloc®
D. Dressler (2006)
10.3109/9781841847559.001
Pharmacology, Immunology and Current Developments
K. Aoki (2006)
10.1111/j.1755-3768.1990.tb01933.x
Long‐term treatment of involuntary facial spasms using botulinum toxin
P. Ruusuvaara (1990)
10.1016/B978-0-7506-9322-6.50028-3
CHAPTER 19 – Diseases of the Eyelids
J. D. Bartlett (1989)
10.1016/0039-6257(91)90207-V
Botulinum A toxin (Oculinum) in ophthalmology.
M. Osako (1991)
10.1136/jnnp.53.8.633
Botulinum toxin treatment of cranial-cervical dystonia, spasmodic dysphonia, other focal dystonias and hemifacial spasm.
J. Jankovic (1990)
10.1067/MJD.2000.105567
Pharmacology of botulinum toxin.
W. Huang (2000)
10.1002/mds.20022
Clinical presentation and management of antibody‐induced failure of botulinum toxin therapy
D. Dressler (2004)
10.1016/S0161-6420(93)31384-9
Serum antibody production to botulinum A toxin.
R. Siatkowski (1993)
10.1007/978-3-642-85173-5_5
Immunodiagnosis and immunotherapy of tetanus and botulinum neurotoxins.
J. Middlebrook (1995)
10.1016/b978-1-4160-4673-8.10007-5
Drug-Induced Ocular Side Effects
F. Fraunfelder (1996)
Análise retrospectiva das alterações da dinâmica facial após aplicações seriadas de toxina botulínica tipo A
S. Paulo. (2006)
10.1016/S0194-5998(97)70117-7
Refinement in the Rehabilitation of the Paralyzed Face using Botulinum Toxin
N. Bikhazi (1997)
10.1212/WNL.41.11.1800
Botulinum‐induced alteration of nerve‐muscle interactions in the human orbicularis oculi following treatment for blepharospasm
K. Alderson (1991)
10.1007/BF00319673
Polyradiculoneuritis following botulinum toxin therapy
B. Haug (2004)
10.1212/WNL.45.9.1743
Response and immunoresistance to botulinum toxin injections
J. Jankovic (1995)
10.1046/j.1468-1331.2001.00035.x
Botulinum toxin type A and other botulinum toxin serotypes: a comparative review of biochemical and pharmacological actions
K. Aoki (2001)
10.1007/978-3-642-85173-5_6
Clinical use of botulinum neurotoxins.
F. Cardoso (1995)
10.1016/j.tox.2013.02.006
Botulinum toxins: mechanisms of action, antinociception and clinical applications.
A. Wheeler (2013)
10.1007/s00115-003-1611-5
Antikörpervermitteltes Versagen der Botulinum-Toxin-Therapie
D. Dressler (2003)
10.1007/s004150070100
Complete secondary botulinum toxin therapy failure in blepharospasm
D. Dressler (2000)
See more
Semantic Scholar Logo Some data provided by SemanticScholar